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Antibiotic resistance inHelicobacter pylori (H.pylori) is the main factor affecting the efficacy
of current treatment methods against infection caused by this organism. The traditional
culture methods for testing bacterial susceptibility to antibiotics are expensive and require
10–14 days. Since resistance to clarithromycin, fluoroquinolone, and tetracycline seems to
be exclusively caused by specific mutations in a small region of the responsible gene,
molecular methods offer an attractive alternative to the above-mentioned techniques.
The technique of polymerase chain reaction (PCR) is an accurate and rapid method for
the detection of mutations that confer antibiotic resistance. This review highlights the
mechanisms of antibiotic resistance in H. pylori and the molecular methods for antibiotic
susceptibility testing.
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INTRODUCTION
H. pylori is identified as a Group 1 carcinogen by theWorldHealth
Organization International Agency for Research on Cancer
(WHO/IARC), and is associated with the development of gas-
tric cancer. Eradication of H. pylori infection has been reported
as an effective strategy in the treatment of peptic ulcers and gas-
tric mucosa-associated lymphoid tissue lymphoma as well as in
the prevention of gastric cancer (Fukase et al., 2008).
Triple treatment including proton pump inhibitor-amoxicillin
and clarithromycin or metronidazole proposed at the first
Maastricht conference is globally accepted as the technique used
to treat H. pylori infection. However, recent data show that effi-
cacy of this combination has decreased, with successful cure in
only 70% patients (Nishizawa et al., 2014). The 4th edition of
the Maastricht consensus recommended a threshold of 15–20%
to separate regions of high and low clarithromycin resistance
(Malfertheiner et al., 2012). In areas of low clarithromycin resis-
tance, treatments containing clarithromycin are recommended as
a first-line empirical treatment. After failure of clarithromycin-
containing therapy, either bismuth-containing quadruple ther-
apy or levofloxacin-containing triple therapy is recommended.
In areas of high clarithromycin resistance, bismuth-containing
quadruple treatments (bismuth subsalicylate, PPI, tetracycline,
and metronidazole) are recommended as a first-line empirical
treatment. After failure of the quadruple therapy, levofloxacin-
containing triple therapy is recommended. After failure of
the second line of treatment, subsequent treatment methods
should be guided by antimicrobial susceptibility testing when-
ever possible. The alternative candidates for third-line therapy are
rifabutin, fluoroquinolones, tetracycline, furazolidone, and high-
dose PPI/amoxicillin therapy (Nishizawa et al., 2008, 2012; Zhang
et al., 2014). The traditional culture test for bacterial suscepti-
bility to antibiotics is requires 10–14 days, and is not routinely
performed in clinical practice. Minimal inhibitor concentration
(MIC)-based individualized treatment for H. pylori infection is
not prevalent among general practitioners. Molecular techniques
for antibiotic susceptibility testing can determine bacterial sus-
ceptibility to some antibiotics within a few days. We reviewed the
mechanisms of antibiotic resistance inH. pylori and themolecular
techniques for antibiotic susceptibility testing.
CLARITHROMYCIN
Clarithromycin resistance possibly results from the use of the
antibiotic in the pediatric, respiratory, and otorhinolaryngology
fields (Kaneko et al., 2004). Global clarithromycin-resistance rates
have increased from 9% in 1998 to 17.6% in 2008 in Europe and
from 7% in 2000 to 27.7% in 2006 in Japan (Asaka et al., 2010).
In patients with clarithromycin-resistant H. pylori, it has been
reported that the eradication rate achieved with clarithromycin-
based regimens shows a marked decrease (Nishizawa et al., 2014).
Therefore, the choice of clarithromycin after drug susceptibility
testing is promising approach.
The bacteriostatic activity of macrolides such as erythromycin
and clarithromycin depends on the capacity to inhibit protein
www.frontiersin.org October 2014 | Volume 1 | Article 19 | 1
MOLECULAR BIOSCIENCES
Nishizawa and Suzuki Resistance mechanisms and molecular test for H. pylori
synthesis by binding to the 23S ribosomal subunit (23S rRNA).
Extensive studies have demonstrated that point mutations in the
peptidyltransferase region encoded in domain V of 23S rRNA are
responsible formacrolide resistance. Thesemutations result in the
inhibition of binding between clarithromycin and the ribosomal
subunit dedicated to specific antibiotic-related protein synthe-
sis (Versalovic et al., 1996). In particular, the main 23S rRNA
mutations include an adenine-to-guanine transition at positions
2142 (11.7%) and 2143 (69.8%), and an adenine-to-cytosine
transversion at position 2142 (2.6%).
Several other point mutations have been identified, such as
A2115G, T2117C, G2141A, T2182C, G2224A, C2245T, T2289C,
C2611A, and T2717C (Francesco et al., 2011). Besides their low
frequency, the clinical relevance of A2115G, T2117C, G2141A,
G2224A, T2289C, C2245T mutations is still not proven. The
T2182C, C2611A, and T2717C have been associated with low
resistance levels (Francesco et al., 2011).
Another relevant mechanism for macrolide resistance is
attributed to the efflux pump system. At least 4 conserved families
of efflux systems associated with bacterial resistance to antibiotics
have been identified (Bina et al., 2000). One of these, widespread
among gram-negative bacteria, is the resistance-nodulation-cell
division (RND) family of efflux systems (Ma et al., 1995). Bina
et al. identified the RND efflux system in H. pylori. HP0605 from
H. pylori is a homolog of the E. coli gene (TolC) encoding the outer
membrane protein, TolC, while HP0607 and HP0606 and are
homologs of the E. coli genes acrA and acrB encoding the mem-
brane fusion and RND cytoplasmic pump protein, respectively
(Bina et al., 2000). Kutschke et al. reported thatHP0607 knockout
mutants exhibited increased susceptibility to penicillin G, cefo-
taxime, erythromycin, clarithromycin, tetracycline, clindamycin,
novobiocin, and ethidium bromide (Kutschke and de Jonge,
2005). We previously investigated the efficacy of efflux pump
inhibitor (Phe-Arg-beta-naphthylamide) in 15 clarithromycin
resistant H. pylori. In all 15 strains, efflux pump mRNA was
expressed, and theMIC of clarithromycin were decreased by using
efflux pump inhibitor, despite possessing 23s rRNA point muta-
tions. In addition, the MIC of clarithromycin was decreased by
the efflux pump inhibitor in a concentration-dependent fashion
(Hirata et al., 2010).
Most clarithromycin-resistant strains of H. pylori have a
A2142G or A2143G mutation. Furuta et al. designed the forward
primer FP2143G and the reverse primer RP2142G, which specif-
ically anneal to A2143G and A2142G mutated sequences of the
H. pylori 23S rRNA gene (Furuta et al., 2007). H. pylori strains
with A2142G, A2143G, and wild-type genotype can be differenti-
ated by amplicon size using the allele-specific, primer-polymerase
chain reaction (PCR) method, which is useful and requires only a
single PCR run.
Wang et al. reported multiplex sequence analysis (Wang et al.,
1999), wherein positions 2142 and 2143 have an AA sequence in
wild-type cells, while mutant cells show a change to GA (A2142G)
and AG (A2143G), respectively. In the presence of dCTP, dATP,
and ddGTP terminating DNA strand elongation results in prod-
ucts of unique length, depending on type of mutation.
Dual priming oligonucleotide (DPO)-PCR is a multiplex
PCR assay that increases specificity and sensitivity of detection
compared to conventional PCR, blocking non-specific binding
sites therefore eliminating imperfect primer annealing. Seeplex®
ClaR-H. pylori ACE detection (Seegene, Inc., Seoul, Korea) is
commercially available DPO-PCR kit to detect H. pylori and
A2142G, A2143G mutations. Although Seeplex® ClaR-H. pylori
ACE detection kit does not allow of detection of A2142C muta-
tion, the mutation is less common (<5% of resistant isolates).
Lehours et al. reported E-test and DPO-PCR were concordant
with regard to clarithromycin susceptibility in 95.3% of the cases
(41/43) (Lehours et al., 2011) (Table 1).
Versalovic et al. developed a method based on rapid restric-
tion analysis of the amplicon obtained from H. pylori (Versalovic
et al., 1996). Single point mutations at positions 2143, 2142,
and 2717 generate specific restriction sites, namely BsaI, MboII,
and HhaI, respectively, which can be used in rapid screening for
clarithromycin resistance (Masaoka et al., 2004). Fontana et al.
developed a new method involving semi-nested PCR and diges-
tion by MboII, BsaI, and HhaI using stool samples. This method
is non-invasive and easy to perform (Fontana et al., 2003).
Klesiewicz et al. evaluated the occurrence of A2143G and
A2142G mutations in 21 H. pylori strains resistant to clar-
ithromycin. The point mutations were detected by PCR followed
by restriction fragment length polymorphism (RFLP) analysis.
Nine H. pylori strains exhibited A2143G mutation and nine
H. pylori strains exhibited A2142G mutation. The results of RFLP
analysis of 3 clarithromycin-resistant strains were negative for
both mutations (Klesiewicz et al., 2014).
Wu et al. evaluated the utility of the string test to detect
genotypic clarithromycin-resistant H. pylori by PCR-RFLP. In the
string test, a 90-cm nylon string coiled inside a gelatin capsule
was used. A free-end looped string protrudes through a hole
in the other end of the capsule. Before the capsule was swal-
lowed, 10–20 cm of the free-end string was pulled out and its
position was ensured by adhesion of a small piece of tape to the
patient’s cheek. It was swallowed with 300mL of water after 8 h
of fasting. One hour after swallowing, the string was retrieved.
Approximately 0.5mL of gastric juice with H. pylori attached
by every 10 cm of the string was reasonable for molecular bio-
logical analysis. Forty three isolates were successfully cultured
in 79 patients in whom 23S rRNA was successfully amplified.
Of 5 patients with clarithromycin-resistant H. pylori, 23S rRNA
of H. pylori isolates from 4 patients could be digested by BsaI.
In 38 susceptible isolates, 23S rRNA of H. pylori isolates from
36 patients could not be digested by either BsaI or BbsI. The
sensitivity and specificity of the string test to detect genotypic
clarithromycin resistance were 66.7 and 97.3%, respectively (Wu
et al., 2014).
The restriction enzyme is capable of identifying an A-to-G
mutation by the creation of a restriction site, but if an A-to-C
mutation occurs, the restriction enzymemay not restrict the DNA
at that site. Stone et al. developed a rapid assay based on PCR
followed by oligonucleotide ligation for rapid detection of these
point mutations, which could differentiate between H. pylori
strains with A2142G, A2143G, A2142C, and wild–type genotype
(Stone et al., 1997).
Several quantitative PCR assays for the determination of clar-
ithromycin susceptibility in H. pylori have subsequently been
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Table 1 | Commercially available molecular methods for H. pylori antibiotics resistance.
Product name Seeplex ClariRes GENECUBE HelicoDR
Manufacturer Seegene Ingenetix TOYOBO Hain Life Science
(Country) (Korea) (Austria) (Japan) (Germany)
Assay technique Dual priming Real-time PCR using Real-time PCR using DNA strip genotyping test combining PCR
oligonucleotide PCR biprobe quenching probe and hybridization
Time-to-result 4 h 30min 6 h
Target gene 23S rRNA 23S rRNA 23S rRNA 23S rRNA gyrA
Detectable mutation A2142G, A2143G A2142G, A2143G A2142G, A2143G A2142G, A2143G 87 (Asn to Lys)
A2142C A2142C 91 (Asp to Gly, Asn, or Tyr)
H. pylori detection Sensitivity 97.7% Sensitivity 100% Sensitivity 100%
Specificity 83.1% Specificity 98–100% Specificity 100%
(Reference test: culture) (Reference test: culture, (Reference test: Hp -IgG,
RUT, histology) RUT, UBT)
Comparison with Sensitivity 100% Sensitivity 94.9% Sensitivity 98.2%
direct sequencing Specificity 100% Specificity 87.1% Specificity 80.0%
Comparison with Concordant rate 95.3% Sensitivity 82-100% Sensitivity 94% Sensitivity 87%
susceptibility test (41/43) Specificity 100% Specificity 99% Specificity 98.5%
UBT: 13C-urea breath test, Hp-IgG: serum anti-H. pylori -IgG, RUT: rapid urease test.
reported. These include a two-step process involving LightCycler
PCR for the detection ofH. pylori followed by melting curve anal-
ysis using probe hybridization to detect resistance (Oleastro et al.,
2003).
GENECUBE® (TOYOBO Co., LTD. Japan) is a novel, fully
automated rapid genetic analyzer capable of extracting nucleic
acids from biological material, preparing reaction mixtures, and
amplifying the target gene all within 30min. The amplified tar-
get DNA is hybridized with a fluoresce-labeled oligonucleotide (a
Qprobe). Upon binding to the target DNA, the Qprobe fluores-
cence is quenched by the guanine bases in the target. However,
the fluorescence reappears as the Qprobe disassociated from the
melting target. By detecting this change in fluorescence inten-
sity, A2143G and A2142G mutations are detected. Furuta et al.
reported the GENECUBE® genotyping results of the 23S rRNA
gene from gastric tissue samples (n = 50) were in complete
agreement with those for direct sequencing. Furthermore, gastric
juice samples were collected during gastroduodenoscopy in 132
patients. Twenty six of the 132 samples were H. pylori-negative
based on analysis of serum anti-H. pylori-IgG, urease and the
13C-urea breath test, and the remaining 106 were H. pylori-
positive. The GENECUBE® could detect H. pylori infection in
all patients infected with H. pylori based on analysis of serum
anti-H. pylori-IgG, urease and the 13C-urea breath test. Thus,
the sensitivity, specificity and validity of the GENECUBE® assay
were all 100% (Furuta et al., 2013). GENECUBE® is commercially
available, it is not approved for clinical diagnostic use (research
use only).
ClariRes® assay (Ingenetix, Vienna, Austria) is a novel com-
mercially available quantitative PCR assay allowing H. pylori
detection and clarithromycin susceptibility testing in either
gastric biopsy or stool specimens. In the biprobe quantitative
PCR protocol, followed by hybridization melting point analysis,
A2143G, A2142G, and A2142C mutations are detected.
Schabereiter et al. evaluated the clinical usefulness of ClariRes®
test in 92 patients who underwent endoscopy. 45 were found to
be H. pylori infected and invariably were also culture positive.
With respect to the detection of H. pylori infection, ClariRes®
test showed sensitivities of 100% and a specificity of 98%. Of
the 45 isolates, 11 were shown to be resistant to clarithromycin
by E-test. Compared to E-test, the sensitivity and specificity of
ClariRes® test for clarithromycin resistance were 82% and 100%
(Schabereiter-Gurtner et al., 2004). Scaletsky et al. evaluated the
clinical usefulness of ClariRes® test in Brazilian children. Forty
five of the 217 samples were H. pylori-positive based on analy-
sis of culture, rapid urease test, or histological examination, and
the remaining 172 were H. pylori-negative. The sensitivity, speci-
ficity and validity of the ClariRes® assay were all 100% for the
detection ofH. pylori infection. In the 45 culture positive patients,
the ClariRes® genotyping results of the 23S rRNA gene from gas-
tric tissue samples were in complete agreement with those for the
E-test (Scaletsky et al., 2011).
Can et al. developed a fluorescent in situ hybridization (FISH)
method to detect H. pylori and determine clarithromycin resis-
tance in formalin-fixed, paraffin-embedded, gastric biopsy spec-
imens (Can et al., 2005). Cerqueira et al. evaluated a peptide
nucleic acid-FISH method for H. pylori clarithromycin resis-
tance detection in paraffin-embedded gastric biopsy specimens.
In the retrospective study (n = 30 patients), full agreement
between peptide nucleic acid-FISH and PCR-sequencing was
observed. Compared to the culture followed by E-test, the speci-
ficity and sensitivity of peptide nucleic acid-FISH were 90.9 and
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84.2%, respectively. In the prospective cohort (n = 93 patients),
21 cases were positive by culture. For the patients harboring
clarithromycin-resistant H. pylori, the method showed sensitivity
of 80.0% and specificity of 93.8% (Cerqueira et al., 2013).
Xuan et al. developed an enzymatic colorimetric DNA chip
(Xuan et al., 2009) including A2142G, A2142C, A2143G, A2143C,
and G2224A mutations, where results were 96.8% (61/63) con-
sistent with those of DNA sequencing. Due to its simplicity
and rapidness, the colorimetric DNA chip might be technically
feasible for use in general clinical practice.
FLUOROQUINOLONES
The primary resistance of H. pylori to fluoroquinolones
has been reported to range between 2–22% in different
countries or regions (Suzuki et al., 2010). Resistance to fluo-
roquinolones is easily acquired, and the resistance rate is rela-
tively high in countries with a high consumption of these drugs
(Nishizawa et al., 2006).
Fluoroquinolones exert their antimicrobial activity by inhibit-
ing the function of the enzyme DNA gyrase (Moore et al., 1995).
The bacterial gyrase is essential for maintaining the DNA heli-
coidal structure in addition to being involved in DNA replication,
recombination and transcription. The gyrase is a tetramer con-
sisting of two A and two B subunits encoded by the gyrA and
gyrB genes, respectively. The A subunit of DNA gyrase is respon-
sible for DNA cleavage and rejoining, is also the site of action
of fluoroquinolones (Matsuzaki et al., 2010). Point mutations
in the Quinolones Resistance-Determining Region (QRDR) of
gyrA prevent binding between the antibiotic and the enzyme,
conferring antibiotic bacterial resistance (Nishizawa et al., 2009).
H. pylori does not possess a gene encoding topoisomerase IV,
an important fluoroquinolone target in other bacteria. Point
mutations in the QRDR of the gyrA gene are mainly at amino
acid 87 (Asn to Lys or Tyr) or 91 (Asp to Gly, Asn, or Tyr).
We previously reported that the MICs of sitafloxacin in gyrA
mutation-positive strains differed, depending on the position
of the gyrA mutation (Suzuki et al., 2009a; Matsuzaki et al.,
2012). The MICs were higher in N87-mutated strains (0.21 ±
0.16μg/ml) than in D91-mutated strains (0.12 ± 0.11μg/ml,
P = 0.03) (Matsuzaki et al., 2012). Rimbara et al. proposed that
mutation at position 463 in gyrB would be a novel mecha-
nism of fluoroquinolone resistance in H. pylori (Rimbara et al.,
2012).
We previously designed the allele-specific primer, which
specifically annealed to the C261A, C261G (87 Asn to Lys), G271A
(91 Asp to Asn), G271T (91 Asp to Tyr), and A272G (91 Asp to
Gly) mutated sequences of the gyrA gene in H. pylori (Nishizawa
et al., 2007). In the allele-specific PCRmethod, PCR amplification
was performed using allele-specific primers in which the second
nucleotide from the 3′ end was designed to match the site of the
point mutation.
Glocker et al. developed a reliable fluorescence resonance
energy transfer-based quantitative PCR method to detect muta-
tions in the gyrA gene (Glocker and Kist, 2004). This method was
developed on DNA extracts from H. pylori isolates from German
patients. Because of the known genetic heterogeneity of H. pylori
(Suerbaum, 2000), the assay may fail with strains isolated outside
Germany, but the test could be altered to adapt to the genetic gyrA
variants found in different geographical regions.
Cambau et al. developed HelicoDR®, a DNA strip genotyp-
ing test combining PCR and hybridization (Cambau et al., 2009)
that allows the molecular detection of mutations in the gyrA
gene and 23S rRNA within 6 h. The sensitivity and specificity
of detecting resistance using this method were 94 and 99% for
clarithromycin and 87% and 98.5% for levofloxacin, respec-
tively. HelicoDR® (Hain Life Science, Germany) is commercially
available.
Lee et al. evaluated the clinical usefulness of HelicoDR® test
in Korea. Both DNA sequencing after MIC test and HelicoDR®
test were performed in H. pylori isolates from the gastric mucosa
of 101 patients. Among 42 isolates with A2143G mutation by
HelicoDR®, 83.3% (35/42) of concordance rate was estimated
with direct sequencing method and 85.7% (36/42) for MIC test.
Among 43 isolates with amino acid 87 (Asn to Lys) mutation
by HelicoDR®, 71.1% (31/43) of concordance rate was esti-
mated with direct sequencing and 88.4% (38/43) for MIC test.
Compared to direct sequencing, the sensitivity and specificity of
HelicoDR® test for 23S rRNA mutation were 94.9 and 87.1%,
and those for gyrA 98.2 and 80.0%. Compared to MIC test, the
sensitivity and specificity of HelicoDR® test for clarithromycin
resistance were 55.0 and 80.0% and those for fluoroquinolone
were 74.4 and 70.0% (Lee et al., 2004).
METRONIDAZOLE
The prevalence of resistance to metronidazole in H. pylori has
been reported to range between 8 and 80% in different coun-
tries (Suzuki et al., 2010). Metronidazole resistance is much
higher in developing countries (more than 60%) than in devel-
oped countries (Banatvala et al., 1994). Metronidazole is a pro-
drug that needs to be activated by reduction of the nitro group
attached to the imidazole ring. This reduction step leads to
the production of DNA-damaging nitroso- and hydroxylamine-
containing compounds. The reduction of metronidazole is
mainly mediated by oxygen-insensitive NADPH nitroreductase
(RdxA), NADPH-flavin-oxidoreductase (FrxA), and ferredoxin-
like enzymes (FrxB) in H. pylori (Francesco et al., 2011).
Different mutations involving the rdxA gene have been identi-
fied in metronidazole-resistant strains (Masaoka et al., 2006).
In the rdxA gene, complex genetic events (insertions and dele-
tions of transposons, and missense and frameshift mutations)
could be simultaneously present. These mutations are recognized
as the main mechanism conferring metronidazole resistance in
H. pylori. Point mutations in frxA and frxB can increase bac-
terial resistance exclusively in the presence of mutations in the
rdxA gene. We previously demonstrated a novel mechanism of
metronidazole resistance in H. pylori, namely, aberrant increase
of superoxide dismutase expression resulting from the muta-
tion of the ferric uptake regulator (Fur) (Tsugawa et al., 2011).
Superoxide dismutase is essential for protection against superox-
ide attack. Superoxide dismutase is derepressed by mutant-type
Fur, which is associated with the development of metronidazole
resistance.
Due to various mutations of rdxA, molecular antibiotic sus-
ceptibility testing is not applicable for metronidazole.
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AMOXICILLIN
The prevalence of resistance to amoxicillin has fortunately
remained low, where most studies have reported it as less than
2% in all countries, except in Bangladesh (6.6%) (Nahar et al.,
2004). Amoxicillin acts by interfering with peptidoglycan synthe-
sis, especially by blocking transporters, namely penicillin binding
proteins (PBP). Multiple mutations in pbp1 gene are the major
reason for amoxicillin resistance. Although amoxicillin resistance
in H. pylori is rare, we previously reported that the MIC90 of
amoxicillin showed a 2-fold increase with the failure of each
eradication treatment (Nishizawa et al., 2011a). Low-level resis-
tant strains (MIC: 0.06–0.25μg/ml) had 0–2 substitutions, while
high-level resistant strains had 1–3 substitutions. Low-level resis-
tance to amoxicillin is linked to a point mutation on pbp1, and
the accumulation of PBP1 mutations could result in a grad-
ual increase in amoxicillin resistance. Although production of
β-lactamase is rare and almost inactive in H. pylori, Tseng et al.
reported that high-level amoxicillin resistance is associated with
β-lactamase production in H. pylori (Tseng et al., 2009). Due to
different mutations of PBP1, molecular antibiotic susceptibility
testing is not applicable for amoxicillin.
TETRACYCLINE
The prevalence of resistance to tetracycline also has fortunately
remained low; it was reported to be less than 2% in most stud-
ies (Suzuki et al., 2010). Tetracyclines are bacteriostatic drugs that
exert their antimicrobial effect on the 30S subunit of the ribosome
and block the binding of aminoacyl-tRNA, resulting in impaired
protein biosynthesis. The resistance of H. pylori to tetracyclines is
reported to be caused bymutations in the 16S rRNA (Gerrits et al.,
2002). Simultaneous triple point-mutations at positions 965–967
are recognized to be major responsible for tetracycline resistance.
Levels of resistance are proportional to the number of changes in
the AGA 965–967. Single and double point-mutations are asso-
ciated with low and intermediate MIC values, respectively. High
resistance levels are observed in the substitution of an AGA with
a TTC triplet.
Ribeiro et al. developed a PCR-RFLP assay allowing rapid
and reproducible identification ofmutationsmediating high-level
tetracycline resistance in H. pylori (Ribeiro et al., 2004). The sub-
stitution of an AGAwith a TTC triplet creates an additionalHinf I
restriction site. This PCR-RFLP assay distinguishes high-level
tetracycline resistant isolates from low-level tetracycline resistant
and tetracycline susceptible H. pylori strains.
Glocker et al. developed real-time PCR to detect 16S rRNA
gene mutations that was capable of differentiating between wild-
type strains and resistant strains exhibiting single-, double-, or
triple-base-pair mutations (Glocker et al., 2005). Future studies
need to address the question of whether additional mutations play
a role in the resistance of H. pylori to tetracycline.
RIFABUTIN
The mean H. pylori rifabutin-resistance rate (calculated from 11
studies including 2982 patients) was 1.3% (Gisbert and Calvet,
2012). When only studies including patients naïve to H. pylori
eradication treatment were considered, this figure was even lower
(0.6%). We previously investigated the resistance to rifabutin
of H. pylori isolated from both general hospital and a hospital
specialized for chronic respiratory disease, including pulmonary
tuberculosis. Among 94 strains tested, 7 (7.4%) were isolated
from patients with a past rifampicin treatment. All these 7 strains
showed high rifabutin resistance (Suzuki et al., 2009b). Rifabutin
is an antituberculous agent derived from rifamycin-S, which is
structurally similar to rifampicin. Rifabutin inhibits the expres-
sion of beta-subunit of DNA-dependent RNA polymerase of
H. pylori, which is encoded by the rpoB gene (Nishizawa et al.,
2011b). Rifabutin-resistant isolates ofH. pylori showedmutations
in codon 149, codons 525 to 545, or codon 586 (Heep et al., 2002).
Due to the different mutations of rpoB, the molecular antibiotic
susceptibility testing is not applicable for rifabutin.
CONCLUSION
Conventional methods used to assess the level of antibiotic-
resistance of H. pylori are culture-based methods used in com-
bination with agar dilution or the E-test. However, because of the
slow growth and particular requirements of H. pylori culture, this
approach is not reliable for use inmost routine clinical laboratory.
Since resistance to clarithromycin, fluoroquinolone, and tetracy-
cline seems to be a result of specific mutations in a small region
of the responsible gene, molecular methods offer an attractive
alternative. Some reliable molecular methods are commercially
available. However, large-scale prospective studies should be per-
formed to assess the full clinical potential of these molecular
methods and its economic feasibility. Users should keep in mind
that whenever possible H. pylori culture should be performed
and only in cases where standard microbiology fails, the use of
molecular methods are really indicated.
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